Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Bahlis NJ, Corso A, Mugge LO, Shen ZX, Desjardins P, Stoppa AM, Decaux O, de Revel T, Granell M, Marit G, Nahi H, Demuynck H, Huang SY, Basu S, Guthrie TH, Ervin-Haynes A, Marek J, Chen G, Facon T. Bahlis NJ, et al. Among authors: demuynck h. Leukemia. 2017 Nov;31(11):2435-2442. doi: 10.1038/leu.2017.111. Epub 2017 Apr 4. Leukemia. 2017. PMID: 28373701 Free PMC article. Clinical Trial.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40.
Rijneveld AW, van der Holt B, Daenen SM, Biemond BJ, de Weerdt O, Muus P, Maertens J, Mattijssen V, Demuynck H, Legdeur MC, Wijermans PW, Wittebol S, Spoelstra FM, Dekker AW, Ossenkoppele GJ, Willemze R, Cornelissen JJ; Dutch-Belgian HOVON Cooperative group. Rijneveld AW, et al. Among authors: demuynck h. Leukemia. 2011 Nov;25(11):1697-703. doi: 10.1038/leu.2011.141. Epub 2011 Jun 7. Leukemia. 2011. PMID: 21647160 Clinical Trial.
A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission.
Vandenberghe P, Verhoef GE, Emonds MP, Demuynck H, Zachée P, De Wolf-Peeters C, Decorte R, Cassiman JJ, Boogaerts MA. Vandenberghe P, et al. Among authors: demuynck h. Leukemia. 1997 Oct;11(10):1775-8. doi: 10.1038/sj.leu.2400810. Leukemia. 1997. PMID: 9324300
Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON.
Daenen S, van der Holt B, Dekker AW, Willemze R, Rijneveld AW, Biemond BJ, Muus P, van de Loosdrecht AA, Schouten HC, van Marwijk Kooy M, Breems DA, Demuynck H, Maertens J, Wijermans PW, Wittebol S, de Klerk EW, Cornelissen JJ; HOVON; Dutch-Belgian Cooperative Group for Hematological Oncology. Daenen S, et al. Among authors: demuynck h. Leukemia. 2012 Jul;26(7):1726-9. doi: 10.1038/leu.2012.53. Epub 2012 Feb 23. Leukemia. 2012. PMID: 22358264 Clinical Trial. No abstract available.
The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.
Schots R, Delforge M, André M, Bries G, Caers J, Demuynck H, De Prijck B, De Samblanx H, Kentos A, Meuleman N, Offner F, Vekemans MC, Vande Broek I, Van Droogenbroeck J, Van de Vanelde A, Wu KL, Doyen C; Multiple Myeloma Study Group of the Belgian Hematological Society. Schots R, et al. Among authors: demuynck h. Acta Clin Belg. 2010 Jul-Aug;65(4):252-64. doi: 10.1179/acb.2010.055. Acta Clin Belg. 2010. PMID: 20954465
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M, Michiels A, Doyen C, Kentos A, Van Droogenbroeck J, Offner F, Bries G, Demuynck H, Vekemans MC, Meuleman N, Mineur PO, Ravoet C, Depryck B, Van de Velde A, Pierre P, Wu KL, Schots R. Delforge M, et al. Among authors: demuynck h. Acta Clin Belg. 2011 Sep-Oct;66(5):371-5. doi: 10.2143/ACB.66.5.2062589. Acta Clin Belg. 2011. PMID: 22145272
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ; FIGHT-AML-301 Investigators. Harousseau JL, et al. Blood. 2009 Aug 6;114(6):1166-73. doi: 10.1182/blood-2009-01-198093. Epub 2009 May 21. Blood. 2009. PMID: 19470696 Free article. Clinical Trial.
Recurrent breakpoints in 14q32.13/TCL1A region in mature B-cell neoplasms with villous lymphocytes.
Urbankova H, Baens M, Michaux L, Tousseyn T, Rack K, Katrincsakova B, Ferreiro JF, van Loo P, de Kelver W, Dierickx D, Demuynck H, Delannoy A, Verschuere J, Jarošová M, de Wolf-Peeters C, Vandenberghe P, Wlodarska I. Urbankova H, et al. Among authors: demuynck h. Leuk Lymphoma. 2012 Dec;53(12):2449-55. doi: 10.3109/10428194.2012.690098. Leuk Lymphoma. 2012. PMID: 22553924
73 results